Guardant Health vs Exact Sciences Which Is a Smarter Choice?

Guardant Health and Exact Sciences are two of the leading companies in the rapidly growing field of cancer diagnostics. Guardant Health specializes in liquid biopsy tests that detect cancer through blood samples, while Exact Sciences focuses on non-invasive screening tests for colorectal cancer. Both companies have seen impressive growth in recent years, but face increasing competition and regulatory challenges. Investors are closely watching their stocks for potential investment opportunities in the ever-expanding market for cancer detection technologies.

Guardant Health or Exact Sciences?

When comparing Guardant Health and Exact Sciences, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Guardant Health and Exact Sciences.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Guardant Health has a dividend yield of -%, while Exact Sciences has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Guardant Health reports a 5-year dividend growth of 0.00% year and a payout ratio of -4.14%. On the other hand, Exact Sciences reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Guardant Health P/E ratio at -8.35 and Exact Sciences's P/E ratio at -52.88. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Guardant Health P/B ratio is -71.17 while Exact Sciences's P/B ratio is 3.53.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Guardant Health has seen a 5-year revenue growth of 0.69%, while Exact Sciences's is 2.73%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Guardant Health's ROE at -1240.25% and Exact Sciences's ROE at -6.75%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $34.20 for Guardant Health and $60.61 for Exact Sciences. Over the past year, Guardant Health's prices ranged from $15.81 to $38.53, with a yearly change of 143.71%. Exact Sciences's prices fluctuated between $40.62 and $79.62, with a yearly change of 96.01%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.